Pnc Financial Services Group, Inc. Alaunos Therapeutics, Inc. Transaction History

Pnc Financial Services Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.5 - $261.0 $100 - $52,200	200 New	200 $0
Q2 2022 Aug 12, 2022	SELL	$0.41 - $1.24 $445 - $1,346	-1,086 Reduced 80.8%	258 $0
Q4 2021 Feb 11, 2022	SELL	$1.09 - $1.89 $21,069 - $36,533	-19,330 Reduced 93.5%	1,344 $1,000
Q3 2021 Nov 05, 2021	SELL	$1.44 - $2.73 $5,448 - $10,330	-3,784 Reduced 15.47%	20,674 $37,000
Q2 2021 Aug 06, 2021	BUY	$2.63 - $3.67 $50,848 - $70,955	19,334 Added 377.32%	24,458 $64,000
Q3 2020 Nov 06, 2020	SELL	$2.39 - $3.43 $60,132 - $86,298	-25,160 Reduced 83.08%	5,124 $12,000
Q2 2020 Aug 07, 2020	SELL	$2.2 - $3.71 $33,004 - $55,657	-15,002 Reduced 33.13%	30,284 $99,000
Q1 2020 May 08, 2020	BUY	$1.9 - $4.98 $28,405 - $74,451	14,950 Added 49.28%	45,286 $110,000
Q3 2019 Nov 08, 2019	BUY	$4.13 - $6.94 $103,250 - $173,500	25,000 Added 468.52%	30,336 $129,000
Q4 2018 Feb 08, 2019	SELL	$1.61 - $3.62 $170,016 - $382,272	-105,600 Reduced 95.19%	5,336 $9,000
Q2 2018 Aug 10, 2018	SELL	$3.02 - $4.94 $1,510 - $2,470	-500 Reduced 0.45%	110,936 $0
Q3 2017 Nov 13, 2017	BUY	$4.99 - $6.57 $556,065 - $732,134	111,436	111,436 $0

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.